论文部分内容阅读
美国食品和药物管理局（FDA）已批准第一种莱姆病疫苗。这种重组外表面蛋白A（OspA）疫苗于0、1和12月接种3剂,用于15～70岁人群预防莱姆病的自动免疫。高危人群是在有大批伯氏疏螺旋体感染蝉出没的草原或林区生活、工作或旅游的人群。FDA称此疫苗接种3剂后能为大多数人提供保护作用,但不能预防所有的莱姆病病例。因此应告知接受疫苗的患者完成全程免疫的重要性,并继续采取标准的预防措施,包括穿保护衣、应用驱蜱剂和灭蜱。
The United States Food and Drug Administration (FDA) has approved the first Lyme disease vaccine. The recombinant outer surface protein A (OspA) vaccine is administered in three doses at 0, 1, and December for the prevention of Lyme disease autoimmunity in the population aged 15- 70 years. High-risk groups are those living, working or traveling in grasslands or forested areas where there are large numbers of Borrelia burgdorferi. The FDA said the vaccine will protect most, but not all, Lyme disease cases. Therefore, patients receiving the vaccine should be informed of the importance of full immunization and to continue taking standard precautions, including wearing protective clothing, applying ticks and tick-killing.